Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain

Osteoarthritis and Cartilage

Volumn 22, Issue 4, 2014, Pages 578-585

  Benschop, R J ^a   Collins, E C ^a   Darling, R J ^a   Allan, B W ^a   Leung, D ^a   Conner, E M ^a   Nelson, J ^a   Gaynor, B ^a   Xu, J ^a   Wang, X F ^a   Lynch, R A ^a   Li, B ^a   McCarty, D ^a   Oskins, J L ^a   Lin, C ^a   Johnson, K W ^a   Chambers, M G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody; CGRP; Meniscal tear; MIA model; Osteoarthritis; Pain

Indexed keywords

ANTIRHEUMATIC AGENT; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; CYCLIC AMP; IODOACETIC ACID; LY 2951742 ANTIBODY; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; UNCLASSIFIED DRUG; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; JOINT DESTRUCTION; MALE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RAT; SKIN BLOOD FLOW; STOICHIOMETRY; ANIMAL; BLOOD FLOW; DISEASE MODEL; DRUG EFFECTS; LEWIS RAT; METABOLISM; PAIN; SKIN; VASCULARIZATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, NEUTRALIZING; CALCITONIN GENE-RELATED PEPTIDE; CATHELICIDINS; DISEASE MODELS, ANIMAL; HUMANS; MALE; OSTEOARTHRITIS; PAIN; RATS; RATS, INBRED LEW; REGIONAL BLOOD FLOW; SKIN;

EID: 84897025557     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.01.009     Document Type: Article

References (37)

1. Hunter D.J., Felson D.T. Osteoarthritis. BMJ 2006, 332:639-642.
2. Mach D.B., Rogers S.D., Sabino M.C., Luger N.M., Schwei M.J., Pomonis J.D., et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002, 113:155-166.
3. Mapp P.I., Kidd B.L., Gibson S.J., Terry J.M., Revell P.A., Ibrahim N.B., et al. Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis. Neuroscience 1990, 37:143-153.
4. Ashraf S., Wibberley H., Mapp P.I., Hill R., Wilson D., Walsh D.A. Increased vascular penetration and nerve growth in the meniscus: a potential source of pain in osteoarthritis. Ann Rheum Dis 2011, 70:523-529.
5. Brain S.D., Grant A.D. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004, 84:903-934.
6. Brain S.D., Williams T.J., Tippins J.R., Morris H.R., MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985, 313:54-56.
7. de Hoon J.N., Pickkers P., Smits P., Struijker-Boudier H.A., Van Bortel L.M. Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin Pharmacol Ther 2003, 73:312-321.
8. Ma W., Chabot J.G., Schorscher-Petcu A., Hong Y., Wang Z., Quirion R. CGRP and adrenomedullin as pin-related peptides. The Calcitonin Gene-related Peptide Family: Form, Function, and Future Perspectives 2010, 151-171. Springer Science+Business Media BV. D.L. Hay, I.M. Dickerson (Eds.).
9. Caterina M.J., Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001, 24:487-517.
10. Van der Schueren B.J., Rogiers A., Vanmolkot F.H., Van Hecken A., Depre M., Kane S.A., et al. Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human invivo pharmacodynamic model. JPharmacol Exp Ther 2008, 325:248-255.
11. Salmon A.M., Damaj M.I., Marubio L.M., Epping-Jordan M.P., Merlo-Pich E., Changeux J.P. Altered neuroadaptation in opiate dependence and neurogenic inflammatory nociception in alpha CGRP-deficient mice. Nat Neurosci 2001, 4:357-358.
12. Zhang L., Hoff A.O., Wimalawansa S.J., Cote G.J., Gagel R.F., Westlund K.N. Arthritic calcitonin/alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain 2001, 89:265-273.
13. Bove S.E., Calcaterra S.L., Brooker R.M., Huber C.M., Guzman R.E., Juneau P.L., et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 2003, 11:821-830.
14. Thakur M., Rahman W., Hobbs C., Dickenson A.H., Bennett D.L. Characterisation of a peripheral neuropathic component of the rat monoiodoacetate model of osteoarthritis. PLoS One 2012, 7:e33730.
15. Bove S.E., Laemont K.D., Brooker R.M., Osborn M.N., Sanchez B.M., Guzman R.E., et al. Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like joint pain and secondary hyperalgesia. Osteoarthritis Cartilage 2006, 14:1041-1048.
16. Pomonis J.D., Boulet J.M., Gottshall S.L., Phillips S., Sellers R., Bunton T., et al. Development and pharmacological characterization of a rat model of osteoarthritis pain. Pain 2005, 114:339-346.
17. Ivanavicius S.P., Ball A.D., Heapy C.G., Westwood F.R., Murray F., Read S.J. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain 2007, 128:272-282.
18. Wu H., Nie Y., Huse W.D., Watkins J.D. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. JMol Biol 1999, 294:151-162.
19. Bendele A.M. Animal models of osteoarthritis. JMusculoskelet Neuronal Interact 2001, 1:363-376.
20. Saxler G., Loer F., Skumavc M., Pfortner J., Hanesch U. Localization of SP- and CGRP-immunopositive nerve fibers in the hip joint of patients with painful osteoarthritis and of patients with painless failed total hip arthroplasties. Eur J Pain 2007, 11:67-74.
21. Takeshita M., Nakamura J., Ohtori S., Inoue G., Orita S., Miyagi M., et al. Sensory innervation and inflammatory cytokines in hypertrophic synovia associated with pain transmission in osteoarthritis of the hip: a case-control study. Rheumatol (Oxford) 2012, 51:1790-1795.
22. Saito T., Koshino T. Distribution of neuropeptides in synovium of the knee with osteoarthritis. Clin Orthop Relat Res 2000, 172-182.
23. Ho T.W., Mannix L.K., Fan X., Assaid C., Furtek C., Jones C.J., et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008, 70:1304-1312.
24. Olesen J., Diener H.C., Husstedt I.W., Goadsby P.J., Hall D., Meier U., et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. NEngl J Med 2004, 350:1104-1110.
25. Zeller J., Poulsen K.T., Sutton J.E., Abdiche Y.N., Collier S., Chopra R., et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 2008, 155:1093-1103.
26. Ferreira-Gomes J., Adaes S., Sarkander J., Castro-Lopes J.M. Phenotypic alterations of neurons that innervate osteoarthritic joints in rats. Arthritis Rheum 2010, 62:3677-3685.
27. Orita S., Ishikawa T., Miyagi M., Ochiai N., Inoue G., Eguchi Y., et al. Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain. BMC Musculoskelet Disord 2011, 12:134.
28. Natura G., von Banchet G.S., Schaible H.G. Calcitonin gene-related peptide enhances TTX-resistant sodium currents in cultured dorsal root ganglion neurons from adult rats. Pain 2005, 116:194-204.
29. Segond von Banchet G., Pastor A., Biskup C., Schlegel C., Benndorf K., Schaible H.G. Localization of functional calcitonin gene-related peptide binding sites in a subpopulation of cultured dorsal root ganglion neurons. Neuroscience 2002, 110:131-145.
30. Bowler K.E., Worsley M.A., Broad L., Sher E., Benschop R., Johnson K., et al. Evidence for anti-inflammatory and putative analgesic effects of a monoclonal antibody to calcitonin gene-related peptide. Neuroscience 2013, 228:271-282.
31. Pavelka K. Acomparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. Curr Med Res Opin 2012, 28:163-178.
32. Staton P.C., Wilson A.W., Bountra C., Chessell I.P., Day N.C. Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol. Eur J Pain 2007, 11:283-289.
33. Hirsch S., Corradini L., Just S., Arndt K., Doods H. The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats. Pain 2013, 154:700-707.
34. Hershey J.C., Corcoran H.A., Baskin E.P., Salvatore C.A., Mosser S., Williams T.M., et al. Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul Pept 2005, 127:71-77.
35. Sinclair S.R., Kane S.A., Van der Schueren B.J., Xiao A., Willson K.J., Boyle J., et al. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol 2010, 69:15-22.
36. Chizh B.A., O'Donnell M.B., Napolitano A., Wang J., Brooke A.C., Aylott M.C., et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007, 132:132-141.
37. Van der Schueren B.J., de Hoon J.N., Vanmolkot F.H., Van Hecken A., Depre M., Kane S.A., et al. Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging. Br J Clin Pharmacol 2007, 64:580-590.